The competitive NMDA receptor antagonist SDZ 220-581 reverses haloperidol-induced catalepsy in rats

European Journal of Pharmacology
K H McAllister

Abstract

The present studies investigated whether SDZ 220-581 ((S)-alpha-amino 2'chloro-5-(phosphonomethyl)[1,1'-biphenyl]-3-propanoic acid), a potent, competitive antagonist at the NMDA glutamate receptor subtype, reversed haloperidol-induced catalepsy in rats, a widely used model of Parkinson's disease. SDZ 220-581 (0.32-3.2 mg/kg i.p.) dose- and time-dependently reduced the time spent in an abnormal position induced by haloperidol (1.0 mg/kg s.c.). Compared to other NMDA receptor antagonists the rank order of potency was MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine) > SDZ 220-581 > SDZ EAA 494 (D-CPPene: (S)-(E)-4-(3-phosphonoprop-2-enyl)-piperazine-2-carboxylic acid) > SDZ EAB 515 ((S)-alpha-amino-5-(phosphonomethyl)[1,1'-biphenyl]-3-propanoic acid). Since it has been demonstrate that SDZ 220-581 counters the effects of L-dihydroxyphenylalanine (L-DOPA) on the motor disturbances of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-pre-treated primates, the results suggest that the reversal of haloperidol-induced catalepsy by competitive NMDA receptor antagonists may not be predictive of efficacy in other models of Parkinson's disease.

References

Jan 1, 1991·Journal of Neural Transmission. Parkinson's Disease and Dementia Section·P A LöschmannC D Marsden
Mar 1, 1989·Pharmacology, Biochemistry, and Behavior·W J Schmidt, M Bubser
Sep 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·E H WongL L Iversen
Jan 1, 1982·The Kurume Medical Journal·Y IdaN Nagasaki
Dec 1, 1994·Neurochemistry International·D A LoweT G White
Jan 1, 1993·Journal of Neural Transmission. General Section·J T Greenamyre
Jun 11, 1993·European Journal of Pharmacology·N A MooreJ D Leander
Jun 1, 1991·Amino Acids·W J SchmidtW Hauber

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here